Medical Devices Australia

Australia Automated Insulin Delivery Systems Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Australia Automated Insulin Delivery Systems Market Industry Trends and Forecast to 2034: Segmented by (Component, Type, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Australia · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $34.0 Mn Placeholder estimate
Estimate 2025 $40.2 Mn 1.1% of the global market
Projected 2034 $182.3 Mn 353.8% Adds $142.1 Mn over 9 forecast years
CAGR 2025–2034 18.3% Faster than 90% of 180 Medical Devices markets here
Key players 6 +1
  • Australia is 1.13% of the global market.
  • In APAC, the largest is China at $266.9 Mn.
  • Fastest growing: India at 20.1% a year.
  • Australia ranks 4th of 10 by size in APAC.

Market size projection

Australia

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$142.1 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Automated Insulin Delivery Systems Market market size by year, Australia
YearMarket sizeChange that yearSince 2025
2024 (estimate) $34.0 Mn — —
2025 (base) $40.2 Mn +$6.2 Mn —
2026 (forecast) $47.5 Mn +$7.4 Mn +18.3%
2027 (forecast) $56.2 Mn +$8.7 Mn +39.9%
2028 (forecast) $66.5 Mn +$10.3 Mn +65.6%
2029 (forecast) $78.7 Mn +$12.2 Mn +95.9%
2030 (forecast) $93.1 Mn +$14.4 Mn +131.7%
2031 (forecast) $110.1 Mn +$17.0 Mn +174.1%
2032 (forecast) $130.2 Mn +$20.1 Mn +224.3%
2033 (forecast) $154.1 Mn +$23.8 Mn +283.6%
2034 (forecast) $182.3 Mn +$28.2 Mn +353.8%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Australia Automated Insulin Delivery Systems Market Analysis at a glance
Market size, 2025$40.2 Mn placeholder estimate
Forecast, 2034$182.3 Mn placeholder estimate
Growth (CAGR), 2025–203418.3% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsComponent, type and end user (see all)
Key playersMedtronic, Tandem Diabetes Care, Insulet Corporation, Dexcom, Inc., Abbott Laboratories and 1 more (see all)
Regulator in AustraliaTGASource: Therapeutic Goods Administration. Checked 14 Nov 2026.
Active clinical trials27 in AustraliaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Australia Automated Insulin Delivery Systems Market Analysis Executive Summary

Automated insulin delivery systems link an insulin pump with a glucose sensor and software that adjusts insulin doses automatically.

Key segments of the automated Insulin Delivery Systems market include component (Insulin Pumps, CGM Sensors and Control Algorithms) and type (Hybrid Closed Loop and Advanced Hybrid Closed Loop).

Bar chart: Australia Automated Insulin Delivery Systems market size, 2024–2034, placeholder estimates. $34.0 Mn in 2024, $40.2 Mn in 2025 and $182.3 Mn in 2034, 18.3% CAGR.
Australia Automated Insulin Delivery Systems market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Australia Automated Insulin Delivery Systems Market Dynamics

Market Growth Drivers

Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the automated Insulin Delivery Systems market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.

Opportunity

Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the automated Insulin Delivery Systems market, especially in fast-growing emerging economies.

Market Restraints

High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the automated Insulin Delivery Systems market. Long-term safety data and lifestyle support are still needed for many patients.

Competitive Landscape for Automated Insulin Delivery Systems Market in Australia

The automated Insulin Delivery Systems market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Automated Insulin Delivery Systems Market in Australia

Automated Insulin Delivery Systems in Australia: rules, payment and research

Medical devices must be included in the Australian Register of Therapeutic Goods (ARTG), run by the Therapeutic Goods Administration (TGA), before they can be supplied.⁠[1] Medicare pays for public hospital care and many doctor visits, and the Pharmaceutical Benefits Scheme (PBS) subsidises listed medicines.⁠[2] ClinicalTrials.gov lists 27 studies on Automated Insulin Delivery Systems that are recruiting, active or about to start in Australia.⁠[3] Diabetes (adults): 8.1% of adults in 2022, the latest WHO figure for Australia.⁠[4]

[1] Therapeutic Goods Administration. Checked 14 Nov 2026.

[2] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 12 Nov 2026.

[4] WHO Global Health Observatory, Diabetes (adults, WHO) (% of adults). Retrieved 20 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how automated Insulin Delivery Systems products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Australia.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Automated Insulin Delivery Systems right now, from free public sources.

Clinical trials

27 active trials in Australia

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. Sanofi 9 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Eli Lilly and Company 9 active trials on ClinicalTrials.gov (opens in a new tab)
  3. Novo Nordisk A/S 9 active trials on ClinicalTrials.gov (opens in a new tab)
  4. Insulet Corporation 5 active trials on ClinicalTrials.gov (opens in a new tab)
  5. Medtronic 5 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 20 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Automated Insulin Delivery Systems in context

Australia compared

  • Diabetes (adults, WHO): 8.1% of adults (2022). World: 14.1% of adults (2022). 16th highest of the 17 countries we cover in APAC.[1]
  • Health spending per person: 6,980 US$ per person (2023). World: 1,317 US$ per person (2023). Highest of the 17 countries we cover in APAC.[2]
  • Doctors: 4.09 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). Highest of the 17 countries we cover in APAC.[3]

[1] WHO Global Health Observatory, Diabetes (adults, WHO) (% of adults). Retrieved 19 Nov 2026.

[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 19 Nov 2026.

[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 19 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Automated Insulin Delivery Systems market in Australia?
Placeholder estimate: about $40.2 Mn in 2025, rising to about $182.3 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Automated Insulin Delivery Systems market in Australia growing?
Placeholder estimate: about 18.3% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Automated Insulin Delivery Systems market report cover?
The report splits the market by component (Insulin Pumps, CGM Sensors, Control Algorithms), type (Hybrid Closed Loop, Advanced Hybrid Closed Loop) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Automated Insulin Delivery Systems market?
Key players include Medtronic, Tandem Diabetes Care, Insulet Corporation, Dexcom, Inc., Abbott Laboratories and Beta Bionics.
What is driving the Automated Insulin Delivery Systems market?
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the automated Insulin Delivery Systems market.
Who regulates Automated Insulin Delivery Systems in Australia?
Medical devices must be included in the Australian Register of Therapeutic Goods (ARTG), run by the Therapeutic Goods Administration (TGA), before they can be supplied. Source: Therapeutic Goods Administration. Checked 14 Nov 2026.
How is healthcare paid for in Australia?
Medicare pays for public hospital care and many doctor visits, and the Pharmaceutical Benefits Scheme (PBS) subsidises listed medicines. Source: Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.
How many clinical trials on Automated Insulin Delivery Systems are running in Australia?
27 studies are recruiting, active or about to start in Australia, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 12 Nov 2026.
What does WHO report for Australia?
Diabetes (adults): 8.1% of adults in 2022, the latest WHO figure. Source: WHO Global Health Observatory, Diabetes (adults, WHO) (% of adults). Retrieved 20 Nov 2026.
How many people in Australia are 65 or older?
18.1% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 19 Nov 2026.
Back to Catalogue

Related Medical Devices reports in Australia

See all

Related on diabetes and remote monitoring and wearables

See the topic